Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...328329330331332333334335336337338...10671068»
  • ||||||||||  Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy. (Available On Demand; 461) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_4150;    
    Peripheral blood plasma and BM samples (n = 186) were obtained at baseline, cycle 3 day 1 (C3D1), end of the study (EOS) and/or relapse, whichever appeared earlier, from a Phase II multicentre single arm study of carfilzomib-thalidomide-dexamethasone (KTd) in 50 TE ND MM patients who were refractory or registered suboptimal response to 1LB (Australasian Leukaemia and Lymphoma Group - MM17 trial)... Our analysis reveals that RAS/RAF and ATM/ATR/TP53 mutations in ctDNA could be prognostic biomarkers of response to secondary salvage therapy in primary refractory patients thus providing the opportunity to design targeted salvage treatment paradigms in high-risk MM patients.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Phase 1b study of weekly split-dose selinexor in soft tissue sarcoma (STS). (Available On Demand; 467) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_3135;    
    P1
    Split-dose selinexor was well tolerated in this heterogeneous group of pts with advanced STS and warrants further interrogation. Updated toxicity, safety, efficacy and QoL data will be presented at the meeting.
  • ||||||||||  dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology
    The effects of AVM0703 mobilization of endogenous gamma delta/invariant TCR+ bispecific natural killer T-like cells against solid tumors and blood cancers. (Available On Demand; 234) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1639;    
    Prophylactic use of circadian physiologic hydrocortisone reduces the risk of GC neuropsychiatric side-effects (Warris LT, et al. AVM0703 led to: i) complete response (CR) in 27% of immune-resistant mouse A20 tumors as monotherapy and CR in 60% when combined with 2 doses of cyclophosphamide/fludarabine (CyFlu); ii) tumor eradication and long-term memory against xenografted human T-ALL; iii) enhancement of ACT equivalent to CyFlu preconditioning in mouse melanoma; and iv) preliminary 95% CR against mouse multiple myeloma.
  • ||||||||||  olanzapine / Generic mfg.
    Efficacy, safety and cost effectiveness of reduced-dose olanzapine versus aprepitant as a part of triple-antiemetic therapy in the prevention of chemotherapy induced nausea and vomiting. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1072;    
    All newly diagnosed cancer patients who were scheduled to receive highly emetogenic chemotherapy (either cisplatin at a dose ≥70 mg/ m2 body surface area, with or without other chemotherapeutic agents, or doxorubicin at a dose of 60 mg/m2 plus cyclophosphamide at a dose of 600 mg /m2) and had a European Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 were randomized 1:1 to receive triple anti emetic regimen comprising of 5HT3 antagonist (Palonosetron)+Steroid (Dexamethasone) + either NK1 antagonist (either Aprepitant 125mg on day 1, 80 mg on days 2, 3 or Fosapprepitant 150mg IV on day 1) or Olanzapine 5mg once daily on days 1-4). In the developing world, Olanzapine 5mg can be considered as an effective, safe, and a cheaper alternate to Aprepitant as a component of triple antiemetic regimen in the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy.
  • ||||||||||  Barhemsys (intravenous amisulpride) / Acacia Pharma
    Intravenous amisulpride as rescue treatment of postoperative nausea and vomiting in patients undergoing oncologic surgical procedures. (Available On Demand; 355) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_917;    
    This subset analysis includes data from a randomized, double-blind, placebo-controlled, multicenter phase III trial of a single 10 mg dose of IV amisulpride as rescue treatment of PONV occurring in patients failing pre/peri-operative prophylaxis, generally with ondansetron and/or dexamethasone (Habib AS, Kranke P, Bergese SD, Chung F, et al. Amisulpride at 10 mg IV is safe and effective as rescue treatment for PONV in cancer patients undergoing surgery and is associated with a marked reduction in PACU length of stay.
  • ||||||||||  Trial primary completion date:  Effects of Pharmacological Stress and RTMS on Executive Function in Opioid Use Disorder (clinicaltrials.gov) -  Apr 28, 2022   
    P2,  N=20, Not yet recruiting, 
    Dexamethasone-based mouthwash safely reduced the incidence and severity of stomatitis in patients receiving chemotherapy (EC/TC) for early breast cancer. Trial primary completion date: Jun 2023 --> Oct 2023
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial primary completion date:  TSM-1: rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers (clinicaltrials.gov) -  Apr 28, 2022   
    P2,  N=20, Not yet recruiting, 
    Trial primary completion date: Jun 2023 --> Oct 2023 Trial primary completion date: Jun 2023 --> Oct 2023
  • ||||||||||  Xhance (fluticasone propionate intranasal spray) / OptiNose
    Trial completion date, Trial primary completion date:  OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps (clinicaltrials.gov) -  Apr 27, 2022   
    P3,  N=120, Recruiting, 
    Trial primary completion date: Jun 2023 --> Oct 2023 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  prednisolone / Generic mfg.
    PUO AND A NASOPHARYNGEAL MASS (MC 2 HALL) -  Apr 27, 2022 - Abstract #ESPID2022ESPID_622;    
    However, due to rapid worsening of her clinical condition upon starting oral prednisolone with increasing hepatosplenomegaly, passage of necrotic material nasally, her steroids were stopped...2. CAEBV may progress to lymphoproliferative disease
  • ||||||||||  carfilzomib / Generic mfg.
    Clinical, Journal:  Carfilzomib-induced thrombotic microangiopathy. A case report. (Pubmed Central) -  Apr 27, 2022   
    Drug-induced thrombotic microangiopathy is a rare and often life-threatening acquired condition whose diagnosis can be challenging and whose therapy is not always limited to supportive treatment and drug avoidance. Carfilzomib, along with other proteasome inhibitors, is one of the described potential drugs which can trigger such a manifestation.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal:  Nivolumab induced hypophysitis in an advanced RCC patient. (Pubmed Central) -  Apr 27, 2022   
    Nivolumab induced hypophysitis is a rare condition that usually presents with fewer symptoms. High degree of clinical suspicion and a multidisciplinary team required to diagnose and treat such cases.
  • ||||||||||  budesonide / Generic mfg.
    Journal, IO biomarker:  Interplay between nuclear factor-κB, p38 MAPK and glucocorticoid receptor signaling synergistically induces functional TLR2 in lung epithelial cells. (Pubmed Central) -  Apr 27, 2022   
    Here, we explore synergy occurring between synthetic glucocorticoids (dexamethasone and budesonide) and proinflammatory cytokines (IL1B and TNF) on the expression of the toll-like receptor 2 (TLR2)...We conclude that glucocorticoid-plus-cytokine-driven synergy at TLR2 involves GR and NF-κB acting via specific enhancer regions, which combined with inhibition of p38α MAPK promotes TLR2 expression. Subsequent inflammatory effects that occur following TLR2 agonism may be pertinent in severe neutrophilic asthma or chronic obstructive pulmonary disease, where glucocorticoid-based therapies are less efficacious.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Endothelial Cell-Targeting, ROS-Ultrasensitive Drug/siRNA Co-Delivery Nanocomplexes Mitigate Early-Stage Neutrophil Recruitment For the Anti-Inflammatory Treatment of Myocardial Ischemia Reperfusion Injury. (Pubmed Central) -  Apr 27, 2022   
    Herein, endothelial cell-targeting and  reactive oxygen species (ROS)-ultrasensitive nanocomplexes (NCs) were developed to mediate efficient co-delivery of VCAM-1 siRNA (siVCAM-1) and dexamethasone (DXM), which cooperatively inhibited neutrophil recruitment by impeding neutrophil migration and adhesion...DXM and siVCAM-1 with complementary functions inhibited both the migration and adhesion of neutrophils, efficiently interventing the neutrophil recruitment and interrupting the self-amplified inflammation cascade in the injured myocardium. The molecular design of RPPT renders an effective example for constructing polymeric materials with high ROS sensitivity, and it resolves the critical dilemma related to polycation-mediated siRNA delivery, such as siRNA encapsulation versus release, and transfection efficiency versus toxicity.
  • ||||||||||  dexamethasone / Generic mfg., hydrocortisone / Generic mfg.
    Journal:  Glucocorticoids inhibit the maturation of committed osteoblasts via SOX2. (Pubmed Central) -  Apr 27, 2022   
    This study demonstrated that GC enhances SOX2 expression in vitro in osteoblast and in vivo in the mice bone, which affects bone-forming activity differently depending on the differentiation stage of osteoblast-lineage cells. Our results provide new insights into prevention and treatment against impaired bone formation in GIO.